Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA.

Schizophr Res. 2008 Aug;103(1-3):104-9. doi: 10.1016/j.schres.2008.04.023. Epub 2008 Jun 4.

PMID:
18534821
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.

Krzystanek M, Krupka-Matuszczyk I.

Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Review.

PMID:
23055416
[PubMed - indexed for MEDLINE]
3.

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.

Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S.

Schizophr Res. 2010 Nov;123(2-3):225-33. doi: 10.1016/j.schres.2010.07.012. Epub 2010 Aug 7. Review.

PMID:
20692814
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

[Current pharmacotherapy of schizophrenia].

Bitter I.

Orv Hetil. 2004 Jan 18;145(3):105-9. Review. Hungarian.

PMID:
15027331
[PubMed - indexed for MEDLINE]
5.

The CATIE schizophrenia trial: results, impact, controversy.

Manschreck TC, Boshes RA.

Harv Rev Psychiatry. 2007 Sep-Oct;15(5):245-58. Review.

PMID:
17924259
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk